FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987040875> ?p ?o ?g. }

• W2987040875 endingPage "196" @default.
• W2987040875 startingPage "186" @default.
• W2987040875 abstract "Background Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis. Functional vitamin K deficiency may further contribute to their susceptibility for VC. We investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation. Methods Patients were randomized to VKAs with target INR 2–3, rivaroxaban 10 mg daily, or rivaroxaban 10 mg daily plus vitamin K2 2000 µ g thrice weekly during 18 months. Systemic dp-ucMGP levels were quantified to assess vascular vitamin K status. Cardiac and thoracic aorta calcium scores and pulse wave velocity were measured to evaluate VC progression. Results Baseline dp-ucMGP was severely elevated in all groups. Initiation or continuation of VKAs further increased dp-ucMGP, whereas levels decreased in the rivaroxaban group and to a larger extent in the rivaroxaban+vitamin K2 group, but remained nevertheless elevated. Changes in coronary artery, thoracic aorta, and cardiac valve calcium scores and pulse wave velocity were not significantly different among the treatment arms. All cause death, stroke, and cardiovascular event rates were similar between the groups. Bleeding outcomes were not significantly different, except for a lower number of life-threatening and major bleeding episodes in the rivaroxaban arms versus the VKA arm. Conclusions Withdrawal of VKAs and high-dose vitamin K2 improve vitamin K status in patients on hemodialysis, but have no significant favorable effect on VC progression. Severe bleeding complications may be lower with rivaroxaban than with VKAs." @default.
• W2987040875 created "2019-11-22" @default.
• W2987040875 creator A5005590845 @default.
• W2987040875 creator A5009074496 @default.
• W2987040875 creator A5019721633 @default.
• W2987040875 creator A5030534862 @default.
• W2987040875 creator A5031972364 @default.
• W2987040875 creator A5039055117 @default.
• W2987040875 creator A5044883146 @default.
• W2987040875 creator A5048572756 @default.
• W2987040875 creator A5050679796 @default.
• W2987040875 creator A5070056448 @default.
• W2987040875 date "2019-11-08" @default.
• W2987040875 modified "2023-10-17" @default.
• W2987040875 title "Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study" @default.
• W2987040875 cites W1969513001 @default.
• W2987040875 cites W1976353014 @default.
• W2987040875 cites W1978587266 @default.
• W2987040875 cites W1979587730 @default.
• W2987040875 cites W1988392476 @default.
• W2987040875 cites W1990618715 @default.
• W2987040875 cites W2006093860 @default.
• W2987040875 cites W2009636451 @default.
• W2987040875 cites W2044483654 @default.
• W2987040875 cites W2050636770 @default.
• W2987040875 cites W2054823150 @default.
• W2987040875 cites W2095804181 @default.
• W2987040875 cites W2110989336 @default.
• W2987040875 cites W2142859473 @default.
• W2987040875 cites W2144461421 @default.
• W2987040875 cites W2150179860 @default.
• W2987040875 cites W2153785016 @default.
• W2987040875 cites W2157125602 @default.
• W2987040875 cites W2162787538 @default.
• W2987040875 cites W2170491971 @default.
• W2987040875 cites W2209637723 @default.
• W2987040875 cites W2272851040 @default.
• W2987040875 cites W2313531523 @default.
• W2987040875 cites W2528808870 @default.
• W2987040875 cites W2571124477 @default.
• W2987040875 cites W2612980975 @default.
• W2987040875 cites W2617039588 @default.
• W2987040875 cites W2793790918 @default.
• W2987040875 cites W2799394337 @default.
• W2987040875 cites W2806816780 @default.
• W2987040875 cites W2809701640 @default.
• W2987040875 cites W2943141374 @default.
• W2987040875 cites W4205645630 @default.
• W2987040875 doi "https://doi.org/10.1681/asn.2019060579" @default.
• W2987040875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6935010" @default.
• W2987040875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31704740" @default.
• W2987040875 hasPublicationYear "2019" @default.
• W2987040875 type Work @default.
• W2987040875 sameAs 2987040875 @default.
• W2987040875 citedByCount "98" @default.
• W2987040875 countsByYear W29870408752020 @default.
• W2987040875 countsByYear W29870408752021 @default.
• W2987040875 countsByYear W29870408752022 @default.
• W2987040875 countsByYear W29870408752023 @default.
• W2987040875 crossrefType "journal-article" @default.
• W2987040875 hasAuthorship W2987040875A5005590845 @default.
• W2987040875 hasAuthorship W2987040875A5009074496 @default.
• W2987040875 hasAuthorship W2987040875A5019721633 @default.
• W2987040875 hasAuthorship W2987040875A5030534862 @default.
• W2987040875 hasAuthorship W2987040875A5031972364 @default.
• W2987040875 hasAuthorship W2987040875A5039055117 @default.
• W2987040875 hasAuthorship W2987040875A5044883146 @default.
• W2987040875 hasAuthorship W2987040875A5048572756 @default.
• W2987040875 hasAuthorship W2987040875A5050679796 @default.
• W2987040875 hasAuthorship W2987040875A5070056448 @default.
• W2987040875 hasBestOaLocation W29870408751 @default.
• W2987040875 hasConcept C126322002 @default.
• W2987040875 hasConcept C127413603 @default.
• W2987040875 hasConcept C164705383 @default.
• W2987040875 hasConcept C2776301958 @default.
• W2987040875 hasConcept C2776704044 @default.
• W2987040875 hasConcept C2776940978 @default.
• W2987040875 hasConcept C2778063415 @default.
• W2987040875 hasConcept C2778661090 @default.
• W2987040875 hasConcept C2779161974 @default.
• W2987040875 hasConcept C2780645631 @default.
• W2987040875 hasConcept C2781037820 @default.
• W2987040875 hasConcept C71924100 @default.
• W2987040875 hasConcept C78519656 @default.
• W2987040875 hasConceptScore W2987040875C126322002 @default.
• W2987040875 hasConceptScore W2987040875C127413603 @default.
• W2987040875 hasConceptScore W2987040875C164705383 @default.
• W2987040875 hasConceptScore W2987040875C2776301958 @default.
• W2987040875 hasConceptScore W2987040875C2776704044 @default.
• W2987040875 hasConceptScore W2987040875C2776940978 @default.
• W2987040875 hasConceptScore W2987040875C2778063415 @default.
• W2987040875 hasConceptScore W2987040875C2778661090 @default.
• W2987040875 hasConceptScore W2987040875C2779161974 @default.
• W2987040875 hasConceptScore W2987040875C2780645631 @default.
• W2987040875 hasConceptScore W2987040875C2781037820 @default.
• W2987040875 hasConceptScore W2987040875C71924100 @default.
• W2987040875 hasConceptScore W2987040875C78519656 @default.
• W2987040875 hasIssue "1" @default.

• next